Favorable Response to High-Dose Infliximab for Refractory Childhood Uveitis

Ophthalmology

Volumn 113, Issue 5, 2006, Pages 860-864.e2

  Kahn, Philip ^a   Weiss, Michael ^b   Imundo, Lisa F ^a   Levy, Deborah M ^a  

^a NewYork Presbyterian Hospital   (United States)

^b The Presbyterian Hospital in the City of New York ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33646163230     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2006.01.005     Document Type: Article

References (34)

1. Rosenberg A.M. Uveitis associated with juvenile idiopathic arthritis. envisioning the future. J Rheumatol 29 (2002) 2253-2255
2. Mochizuki M., Masuda K., Sakane T., et al. A clinical trial of FK506 in refractory uveitis. Am J Ophthalmol 115 (1993) 763-769
3. Rosenbaum J.T. Treatment of severe refractory uveitis with intravenous cyclophosphamide. J Rheumatol 21 (1994) 123-125
4. Kilmartin D.J., Forrester J.V., and Dick A.D. Cyclosporin A therapy in refractory non-infectious childhood uveitis. Br J Ophthalmol 82 (1998) 737-742
5. Goldstein D.A., Fontanilla F.A., Kaul S., et al. Long-term follow-up of patients treated with short-term high-dose chlorambucil for sight-threatening ocular inflammation. Ophthalmology 109 (2002) 370-377
6. Baltatzis S., Tufail F., Yu E.N., et al. Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology 110 (2003) 1061-1065
7. Maini R., St. Clair E.W., Breedveld F., et al., ATTRACT Study Group. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate. a randomised phase III trial. Lancet 354 (1999) 1932-1939
8. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. ACCENT I Study Group. Maintenance infliximab for Crohn's disease. the ACCENT I randomised trial. Lancet 359 (2002) 1541-1549
9. De Vos A.F., Hoekzema R., and Kijlstra A. Cytokines and uveitis, a review. Curr Eye Res 11 (1992) 581-597
10. Franks W.A., Limb G.A., Stanford M.R., et al. Cytokines in human intraocular inflammation. Curr Eye Res 11 suppl (1992) 187-191
11. Santos Lacomba M., Marcos Martin C., Gallardo Galera J.M., et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res 33 (2001) 251-255
12. Sfikakis P.P., Theodossiadis P.G., Katsiari C.G., et al. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. [letter]. Lancet 358 (2001) 295-296
13. Joseph A., Raj D., Dua H.S., et al. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 110 (2003) 1449-1453
14. El-Shabrawi Y., and Hermann J. Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology 109 (2002) 2342-2346
15. Murphy C.C., Ayliffe W.H., Booth A., et al. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 111 (2004) 352-356
16. Keane J., Gershon S., Wise R.P., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345 (2001) 1098-1104
17. BenEzra D., Forrester J.V., Nussenblatt R.B., et al. Uveitis Scoring System (1991), Springer-Verlag, Berlin 1-9
18. Brito B.E., O'Rourke L.M., Pan Y., et al. IL-1 and TNF receptor-deficient mice show decreased inflammation in an immune complex model of uveitis. Invest Ophthalmol Vis Sci 40 (1999) 2583-2589
19. Kulkarni P.S., and Srinivasin B.D. Cachectin. a novel polypeptide induces uveitis in the rabbit eye. Exp Eye Res 46 (1988) 631-633
20. Dick A.D., Duncan L., Hale G., et al. Neutralizing TNF-alpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis. J Autoimmun 11 (1998) 255-264
21. Robertson M., Liversidge J., Forrester J.V., and Dick A.D. Neutralizing tumor necrosis factor-alpha activity suppresses activation of infiltrating macrophages in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 44 (2003) 3034-3041
22. Kasner L., Chan C.C., Whitcup S.M., and Gery I. The paradoxical effect of tumor necrosis factor alpha (TNF-alpha) in endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 34 (1993) 2911-2917
23. Smith J., Levinson R., Holland G.N., et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 45 (2001) 252-257
24. Kaipiainen-Seppanen O., and Leino M. Recurrent uveitis in a patient with juvenile spondyloarthropathy associated with tumour necrosis factor alpha inhibitors. Ann Rheum Dis 62 (2003) 88-89
25. Reddy A.R., and Backhouse O.C. Does etanercept induce uveitis?. Br J Ophthalmol 87 (2003) 925 [letter]
26. Samson C.M., Waheed N., Baltatzis S., and Foster C.S. Methotrexate therapy for chronic noninfectious uveitis. analysis of a case series of 160 patients. Ophthalmology 108 (2001) 1134-1139
27. de Boer J., Wulffraat N., and Rothova A. Visual loss in uveitis of childhood. Br J Ophthalmol 87 (2003) 879-884
28. Reiff A., Takei S., Sadeghi S., et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 44 (2001) 1411-1415
29. Foster C.S., Tufail F., Waheed N.K., et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 121 (2003) 437-440
30. Klapman J.B., Ene-Stoescu D., Becker M.A., and Hanauer S.B. A lupus-like syndrome associated with infliximab therapy. Inflamm Bowel Dis 9 (2003) 176-178
31. Khanna D., McMahon M., and Furst D.E. Anti-tumor necrosis factor alpha therapy and heart failure. what have we learned and where do we go from here?. Arthritis Rheum 50 (2004) 1040-1050
32. Miele E., Markowitz J.E., Mamula P., and Baldassano R.N. Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr 38 (2004) 502-508
33. Maini R.N., Breedveld F.C., Kalden J.R., et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41 (1998) 1552-1563
34. Braun J., Baraliakos X., Brandt J., et al. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology 44 (2005) 670-676